Oligometastatic prostate cancer refers to the cases affecting a group of patients with a potentially highly favorable limited metastatic state, defined exclusively by clinical features.1 The cases affecting this group challenge the long-held oncological paradigm that metastasis from solid-organ malignant conditions are not controllable and thus should be managed with palliative intent. In the wake of the US Preventive Services Task Force 2012 recommendation against routine prostate-specific antigen screening, de novo metastatic prostate cancer incidence has experienced a relative increase of 57.1% (from 4.9% to 7.7%; P = .08), equating to an expected 15 097 diagnoses per year by 2025.2 Nonetheless, overall survival in this group of patients has also dramatically increased with the use of early, novel systemic agents, such as docetaxel.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Connor MJ, Winkler M, Ahmed HU. Survival in Oligometastatic Prostate Cancer—A New Dawn or the Will Rogers Phenomenon? JAMA Oncol. 2020;6(2):185–186. doi:10.1001/jamaoncol.2019.4724
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: